In the first half of 2024, it seemed Eli Lilly (NYSE: LLY) could do no wrong. Is Eli Lilly a good stock to buy on the dip? On Jan. 14, CEO David Ricks told investors that 2024 sales would come in at ...

You can look at the momentum for some stocks and have a feeling that it's about to end. Others, though, have such strong ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Also, Lilly looks well placed to get approval for several new drugs and label expansions for marketed drugs, including Mounjaro and Zepbound ... Stocks Set to Double like Nano-X Imaging which ...

Financial writer cautious on Eli Lilly stock despite strong performance, citing high valuation and underperforming drugs.

Other “experts” look at past growth rates and assign ... increased market activity and volatility. Peptide drugs like Mounjaro and Zepbound currently require injections, but the biotech ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

GLP-1 drugs do a lot more than just help you lose weight. They can help your heart, brain, and more, but beware what they ...

Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...

We recently published a list of 10 Best Blue Chip Stocks to Buy for 2025. In this article, we are going to take a look at ...

The company boasts of a robust pipeline of glucagon-like peptide-1 (GLP-1) receptor agonist drugs. Eli Lilly and Company’s (NYSE:LLY) Mounjaro and Zepbound ... as it also looks to diversify ...